Company intelligence / Profile preview

BIT Pharma

Ownership: Private
Development stage: Phase 2

Overview

BIT Pharma's lead program, NicaPlant® (a nicardipine-releasing brain implant), has demonstrated positive results in a Phase IIb randomized clinical trial for the prevention of vasospasm after aneurysmal subarachnoid hemorrhage. Results were published in JAMA Neurology in August2024[9]. The company focuses on innovative site-specific drug delivery to the central nervous system for high-need neurological indications.

Therapeutic areas: Neurology
Modalities: Small moleculesDrug delivery implants
Industry: Biotech

Drug pipeline

1 asset

nicardipine

Phase 2

Indications: Non-traumatic subarachnoid hemorrhage

Beyond the preview

Go deeper on BIT Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIT Pharma.

Explore the full profile